|
 The company's shares were down 6.6 percent at $155 in extended
trading on Thursday.
Intercept said the FDA would now announce its decision on May 29 as
it required more time to analyze additional clinical data submitted
by the company.
The drug, Obeticholic Acid, is to treat primary biliary cirrhosis (PBC),
a rare liver disease that results from autoimmune destruction of the
bile ducts in the liver.
Intercept is seeking approval for the drug to be used in combination
with a generic liver drug called ursodeoxycholic acid.
The company is also conducting late-stage studies on the same drug
to treat Nonalcoholic Steatohepatitis (NASH), which has no approved
treatment.
The NASH indication remains the jewel in Intercept's pipeline.
"The obvious longer-term ICPT reality is this is a NASH story not a
PBC story and expectations don't seem overly high for PBC," RBC
analyst Michael Yee said in a note earlier this month.
[to top of second column] |
"The bigger picture value creation will likely be driven by success
in NASH."
After Gilead Sciences Inc hit the jackpot with its hepatitis C
drugs, Sovaldi and Harvoni, drugmakers have been turning their
attention to other liver diseases.
(Reporting by Amrutha Penumudi in Bengaluru; Editing by Savio
D'Souza)
[© 2015 Thomson Reuters. All rights
reserved.] Copyright 2015 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
 |
